218 related articles for article (PubMed ID: 31217827)
41. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells.
Cooney CA; Jousheghany F; Yao-Borengasser A; Phanavanh B; Gomes T; Kieber-Emmons AM; Siegel ER; Suva LJ; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
Breast Cancer Res; 2011 Jun; 13(3):R58. PubMed ID: 21658254
[TBL] [Abstract][Full Text] [Related]
42. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
[TBL] [Abstract][Full Text] [Related]
43. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
44. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
[TBL] [Abstract][Full Text] [Related]
45. CSPG4 in cancer: multiple roles.
Wang X; Wang Y; Yu L; Sakakura K; Visus C; Schwab JH; Ferrone CR; Favoino E; Koya Y; Campoli MR; McCarthy JB; DeLeo AB; Ferrone S
Curr Mol Med; 2010 Jun; 10(4):419-29. PubMed ID: 20455858
[TBL] [Abstract][Full Text] [Related]
46. A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma.
Alegre F; Ormonde AR; Snider KM; Woolard K; Yu AM; Wittenburg LA
PLoS One; 2018; 13(12):e0209941. PubMed ID: 30596759
[TBL] [Abstract][Full Text] [Related]
47. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
[TBL] [Abstract][Full Text] [Related]
48. Telomerase activity in canine osteosarcoma.
Kow K; Bailey SM; Williams ES; Withrow S; Lana SE
Vet Comp Oncol; 2006 Sep; 4(3):184-7. PubMed ID: 19754815
[TBL] [Abstract][Full Text] [Related]
49. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
[TBL] [Abstract][Full Text] [Related]
50. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
Javaid S; Terai K; Dudek AZ
Anticancer Res; 2015 Mar; 35(3):1279-84. PubMed ID: 25750275
[TBL] [Abstract][Full Text] [Related]
51. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
Front Oncol; 2022; 12():804466. PubMed ID: 35280756
[TBL] [Abstract][Full Text] [Related]
52. Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma.
Yang YT; Engleberg AI; Yuzbasiyan-Gurkan V
Cells; 2023 Dec; 13(1):. PubMed ID: 38201229
[TBL] [Abstract][Full Text] [Related]
53. Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation.
Yang J; Liao Q; Price M; Moriarity B; Wolf N; Felices M; Miller JS; Geller MA; Bendzick L; Hopps R; Starr TK; O'Connor CH; Tarullo S; Nelson AC; Turley E; Wang J; McCarthy JB
Transl Oncol; 2022 Feb; 16():101318. PubMed ID: 34942534
[TBL] [Abstract][Full Text] [Related]
54. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration.
Winship A; Van Sinderen M; Heffernan-Marks A; Dimitriadis E
Int J Oncol; 2017 Mar; 50(3):798-804. PubMed ID: 28098860
[TBL] [Abstract][Full Text] [Related]
55. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts.
Fenton M; Whiteside TL; Ferrone S; Boyiadzis M
Oncol Res; 2015; 22(2):117-21. PubMed ID: 25706398
[TBL] [Abstract][Full Text] [Related]
56. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
[TBL] [Abstract][Full Text] [Related]
57. Proteomic Analyses Reveal the Role of Alpha-2-Macroglobulin in Canine Osteosarcoma Cell Migration.
Wilk SS; Michalak K; Owczarek EP; Winiarczyk S; Zabielska-Koczywąs KA
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612805
[TBL] [Abstract][Full Text] [Related]
58. Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma.
Chen K; Yong J; Zauner R; Wally V; Whitelock J; Sajinovic M; Kopecki Z; Liang K; Scott KF; Mellick AS
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428658
[TBL] [Abstract][Full Text] [Related]
59. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
[TBL] [Abstract][Full Text] [Related]
60. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
